AG-825
Modify Date: 2024-01-20 18:35:57
AG-825 structure
|
Common Name | AG-825 | ||
|---|---|---|---|---|
| CAS Number | 149092-50-2 | Molecular Weight | 397.471 | |
| Density | 1.5±0.1 g/cm3 | Boiling Point | 689.3±65.0 °C at 760 mmHg | |
| Molecular Formula | C19H15N3O3S2 | Melting Point | N/A | |
| MSDS | USA | Flash Point | 370.7±34.3 °C | |
Use of AG-825AG-825 (Tyrphostin AG-825) is a selective and ATP-competitive ErbB2 inhibitor which suppresses tyrosine phosphorylation, with an IC50 of 0.35 μM. AG-825 displays anti-cancer activity[1][2][3]. AG825 significantly accelerates apoptosis of human neutrophils[4]. AG-825 is a potential agent for overcoming Mn-induced neurotoxicity or AD development[5]. |
| Name | ag 825 |
|---|---|
| Synonym | More Synonyms |
| Description | AG-825 (Tyrphostin AG-825) is a selective and ATP-competitive ErbB2 inhibitor which suppresses tyrosine phosphorylation, with an IC50 of 0.35 μM. AG-825 displays anti-cancer activity[1][2][3]. AG825 significantly accelerates apoptosis of human neutrophils[4]. AG-825 is a potential agent for overcoming Mn-induced neurotoxicity or AD development[5]. |
|---|---|
| Related Catalog | |
| Target |
ErbB2:0.35 μM (IC50) EGFR:19 μM (IC50) |
| References |
| Density | 1.5±0.1 g/cm3 |
|---|---|
| Boiling Point | 689.3±65.0 °C at 760 mmHg |
| Molecular Formula | C19H15N3O3S2 |
| Molecular Weight | 397.471 |
| Flash Point | 370.7±34.3 °C |
| Exact Mass | 397.055481 |
| PSA | 162.77000 |
| LogP | 2.89 |
| Vapour Pressure | 0.0±2.2 mmHg at 25°C |
| Index of Refraction | 1.733 |
| Storage condition | −20°C |
| Water Solubility | DMSO: soluble |
| Personal Protective Equipment | Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter |
|---|---|
| Safety Phrases | 22-24/25 |
| RIDADR | NONH for all modes of transport |
| WGK Germany | 3 |
|
Endogenous expression of the sodium iodide symporter mediates uptake of iodide in murine models of colorectal carcinoma.
Int. J. Cancer 125(12) , 2783-91, (2009) The sodium iodide symporter (NIS) mediates iodide uptake into the thyroid. Because of this mechanism, differentiated thyroid cancer is susceptible for radioiodine therapy. Functional NIS expression in... |
|
|
Degradation of HER2 receptor through hypericin-mediated photodynamic therapy.
Photochem. Photobiol. 86 , 200-5, (2010) Current treatment of breast cancer is often affected by resistance to therapeutics, for which the human epidermal growth factor receptor 2 (HER2) may be responsible. Here, we report for the first time... |
| 2-Propenamide, 3-[3-[(2-benzothiazolylthio)methyl]-4-hydroxy-5-methoxyphenyl]-2-cyano-, (2E)- |
| (2E)-3-{3-[(1,3-Benzothiazol-2-ylsulfanyl)methyl]-4-hydroxy-5-methoxyphenyl}-2-cyanoacrylamide |
| TYRPHOSTIN C15 |
| (2E)-3-{3-[(1,3-benzothiazol-2-ylsulfanyl)methyl]-4-hydroxy-5-methoxyphenyl}-2-cyanoprop-2-enamide |
| 5-[(Benzothiazol-2-yl)thiomethyl]-4-hydroxy-3-methoxybenzylidenecyanoacetamide Tyrphostin C15 |